Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Cash (2019 - 2025)

Historic Change in Cash for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$14.5 million.

  • Allogene Therapeutics' Change in Cash rose 8784.46% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 2545.12%. This contributed to the annual value of -$7.9 million for FY2024, which is 13734.88% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Change in Cash of -$14.5 million as of Q3 2025, which was up 8784.46% from $9.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Change in Cash's 5-year high stood at $119.6 million during Q2 2024, with a 5-year trough of -$119.4 million in Q3 2024.
  • Its 5-year average for Change in Cash is -$7.6 million, with a median of -$13.4 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Change in Cash was 28888.7% (2023), while the steepest drop was 29435.53% (2023).
  • Over the past 5 years, Allogene Therapeutics' Change in Cash (Quarter) stood at -$15.9 million in 2021, then increased by 21.5% to -$12.5 million in 2022, then skyrocketed by 211.69% to $13.9 million in 2023, then skyrocketed by 72.4% to $24.0 million in 2024, then plummeted by 160.54% to -$14.5 million in 2025.
  • Its Change in Cash stands at -$14.5 million for Q3 2025, versus $9.9 million for Q2 2025 and -$32.8 million for Q1 2025.